Acute and chronic ethanol increases reactive oxygen species generation and decreases viability in fresh, isolated rat hepatocytes.
Although reactive oxygen species (ROS) have been implicated in the etiology of alcohol-induced liver disease, neither their relative contribution to cell death nor the cellular mechanisms mediating their formation are known. The purpose of this study was to test the hypothesis that acute and chronic ethanol exposure enhances the mitochondrial generation of ROS in fresh, isolated hepatocytes. Acute ethanol exposure stimulated ROS production, increased the cellular NADH/NAD+ ratio, and decreased hepatocyte viability slightly, which was prevented by pretreatment with 4-methylpyrazole (4-MP), an inhibitor of alcohol dehydrogenase. Similarly, xylitol, an NADH-generating compound, enhanced hepatocyte ROS production and decreased viability. Incubation with pyruvate, an NADH-oxidizing compound, and cyanamide, an inhibitor of aldehyde dehydrogenase, significantly decreased ROS levels in acute ethanol-treated hepatocytes. Chronic ethanol consumption produced a sixfold increase in hepatocyte ROS production compared with levels measured in controls. Hepatocytes from ethanol-fed rats were less viable compared with controls, e.g., viability was 68% +/- 2% (ethanol) versus 83% +/- 1% (control) after 60 minutes of incubation. Antimycin A increased ROS production and decreased cell viability; however, the toxic effect of antimycin A was more pronounced in ethanol-fed hepatocytes. These results suggest that acute and chronic ethanol exposure exacerbates mitochondrial ROS production, contributing to cell death.
Bailey
S M
SM
Department of Biochemistry, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Cunningham
C C
CC
D000426:Alcohol Dehydrogenase / Q000037:antagonists & inhibitors; D000818:Animals; D002470:Cell Survival / Q000187:drug effects*; D003484:Cyanamide / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D000431:Ethanol / Q000008:administration & dosage / Q000494:pharmacology*; D000077604:Fomepizole; D007700:Kinetics; D008099:Liver / Q000166:cytology / Q000378:metabolism*; D008108:Liver Diseases, Alcoholic / Q000209:etiology; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects / Q000378:metabolism; D009243:NAD / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology; D019289:Pyruvic Acid / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism*; D014993:Xylitol / Q000494:pharmacology
D004791:Enzyme Inhibitors; D011720:Pyrazoles; D017382:Reactive Oxygen Species; D009243:NAD; D000431:Ethanol; D003484:Cyanamide; D000077604:Fomepizole; D019289:Pyruvic Acid; D000426:Alcohol Dehydrogenase; D014993:Xylitol